Global Medtech Trends 2026: How Pricing, Care Delivery, and Technology Are Redrawing the Industry

Executive Summary

The global medical technology (medtech) industry is at a pivot point. A convergence of pricing pressure, shifting care settings, supply chain disruption, and digital integration is forcing manufacturers, investors, and health systems to rethink long-held assumptions. Clarivate's latest report highlights five defining trends for 2026: Mainland China's expanding volume-based procurement (VBP) scheme, the accelerated migration of procedures to ambulatory surgical centers (ASCs), trade-driven supply chain reengineering, the clinical and commercial ripple effects of GLP-1 receptor agonists, and the emergence of platform-based competition enabled by robotics and digital workflows. Each trend carries significant cross-border implications, influencing where value is created, how companies compete, and what policy frameworks might evolve.

Introduction

Medical technology has long been a sector defined by innovation cycles and regulatory milestones. But in 2026, the industry's center of gravity is shifting. Macroeconomic pressures, geopolitical tensions, and changing patient behaviors are creating a complex operating environment where success depends as much on supply chain architecture and market access as on clinical performance. This article explores the forces that will shape global medtech in the coming year, drawing on insights from Clarivate's annual industry analysis.

Background & Context

For the past decade, medtech growth has been driven by aging populations, rising chronic disease prevalence, and technological advances. However, the industry now faces a paradox: while demand for devices continues to climb, the economics of healthcare delivery are tightening worldwide. Governments and payers are increasingly leveraging procurement power to compress prices, while providers are shifting care to lower-cost settings. At the same time, the global trade environment has become less predictable, and new therapeutic classes are altering patient pathways. These tendencies are not isolated; they are interconnected, amplifying each other across markets.

Main Analysis

1. China's Volume-Based Procurement: Redefining Global Pricing Dynamics

Mainland China's VBP program, initially established to expand access to essential medical devices, has evolved into a sophisticated market reform mechanism. The latest procurement rounds introduce more complex anchoring logic, deeper price cuts, and allocation rules that favor domestic manufacturers. For multinational companies, participation in VBP is no longer optional, but it comes with strategic trade-offs. The program's scale—China represents a substantial share of global device consumption—means that pricing decisions made in Beijing increasingly influence reference pricing in other emerging markets and even in developed economies. Multinationals are being forced to segment their product portfolios, separating high-end devices from volume-optimized offerings, and to consider local partnership models. The global implication is clear: the era of uniform global pricing is ending.

2. Outpatient and ASC Settings: Reshaping Procedure Strategies

The migration of surgical procedures from hospital inpatient facilities to outpatient and ambulatory surgical centers continues to accelerate. In the U.S., the 2026 CMS final rule expands the covered procedures list for ASCs, enabling higher-acuity interventions such as cardiac ablation to be performed in these settings. This shift is not unique to the United States; similar trends are visible in Europe and parts of Asia as health systems seek to reduce costs and improve efficiency. For medtech manufacturers, the move requires a fundamental rethink of product design (smaller, more portable devices), commercial models (value-based purchasing), and clinical evidence generation (demonstrating safety and efficacy outside the hospital). The competitive advantage will increasingly accrue to companies that can tailor their offerings to the specific needs of ambulatory surgery centers, which often have stricter space and reimbursement constraints.

3. Supply Chain Pressures: Tariffs, Diversification, and Manufacturing Footprints

Global trade dynamics are reshaping the medtech manufacturing landscape. Tariff increases, particularly on goods traded between major economies, have raised input costs and forced companies to reassess their production footprints. In response, firms are diversifying sourcing, building multi-region manufacturing capacity, and investing in automation to mitigate labor and logistics risks. This rebalancing has implications for global supply chains, potentially leading to regionalization and the emergence of new manufacturing hubs. For the industry, supply chain resilience is moving from a back-office concern to a board-level priority. Companies that can maintain flexibility while containing costs will be better positioned to withstand both tariff shocks and geopolitical disruptions. Moreover, this trend is likely to influence foreign direct investment as medtech firms expand or relocate facilities in countries offering favorable trade conditions and incentives.

4. The GLP-1 Wave: Transforming Metabolic Care and Adjacent Device Markets

The rapid adoption of GLP-1 receptor agonists for obesity and type 2 diabetes is having a pronounced effect on medical technology. While bariatric surgery remains the gold standard for weight loss, GLP-1s are changing referral patterns and reducing demand for certain bariatric procedures. The impact extends beyond metabolic surgery to related fields, including diabetes care, cardiovascular monitoring, and even sleep apnea management, as weight loss alters disease progression. For device makers, this represents both a threat and an opportunity. Companies that can align with the GLP-1 ecosystem—for example, by developing companion diagnostics or monitoring devices—will find new avenues for growth, while those dependent on procedures that are being displaced will need to adapt. Globally, the GLP-1 effect underscores the growing interconnectedness of pharmaceutical and device markets, as therapeutic breakthroughs reshape clinical pathways across specialties.

5. Enabling Technologies: Platform-Based Competition

Advanced enabling technologies—robotics, imaging, navigation systems, and digital workflows—are becoming central to medtech differentiation. These tools are no longer standalone products; they are components of integrated platforms that support the entire surgical cycle, from planning to execution to follow-up. Companies are investing heavily in proprietary ecosystems that anchor hospital relationships and generate valuable clinical data. At the same time, open-platform architectures are gaining traction, allowing third-party devices and software to integrate, which could disrupt closed models. The competitive dynamics are shifting from individual device excellence to platform coverage and interoperability. This has international ramifications, as platform standardization can influence surgical practice patterns across borders, raising questions about data sovereignty, interoperability standards, and market access.

Global Impact

The five trends are not isolated; they are interlinked and have collective global consequences. China's VBP pressures are forcing multinationals to recalibrate global pricing structures, potentially leading to more differentiated pricing across markets. The shift to ASCs is encouraging investment in outpatient infrastructure and value-based care models, which may foster new types of healthcare delivery enterprises with cross-border scalability. Supply chain diversification will reshape trade flows, alter the competitiveness of manufacturing nations, and influence bilateral investment treaties. The GLP-1 effect is likely to change the prevalence of obesity-related procedures worldwide, with implications for public health and healthcare budgeting. Finally, platform-based competition will accelerate the convergence of medical devices and digital technology, demanding new skills, regulations, and international standards.

Strategic Insights

For business executives and investors, these trends suggest several strategic imperatives:

• Portfolio agility: Companies must regularly reassess their product mix, balancing high-growth innovative devices against those exposed to pricing or demand erosion.
• Regional nuance: Pricing and market access strategies need to be tailored by region, particularly for China and other emerging markets.
• Supply chain resilience: Development of flexible, multi-region sourcing and manufacturing will be critical for maintaining margins and meeting regulatory expectations.
• Clinical pathway integration: Device companies should engage with pharmaceutical firms and digital health providers to orchestrate care pathways around metabolic diseases and other chronic conditions.
• Ecosystem partnerships: Success in enabling technologies will depend on partnerships across robotics, imaging, and data analytics firms, as well as on openness to third-party integration.

Future Outlook

Looking ahead to 2030, the medtech industry will likely be more consolidated, regionalized, and digitally integrated. Pervasive adoption of artificial intelligence and machine learning will enable predictive maintenance, personalized implants, and automated surgical assistance. Value-based procurement will extend beyond China, putting pressure on manufacturers to prove outcomes. The rise of home-based care may further blur the line between medical devices and consumer electronics. Geopolitical fragmentation could lead to the creation of parallel regulatory and manufacturing blocs, raising compliance costs. However, these challenges also present opportunities for companies that can innovate across borders and contribute to global health systems that are increasingly focused on access, affordability, and sustainability.

Conclusion

The forces identified in Clarivate's analysis are not transient; they represent structural changes in the global medtech landscape. Companies that embrace these shifts—by rethinking pricing, expanding into ambulatory settings, diversifying supply chains, adapting to therapeutic disruption, and investing in platform technologies—will be better placed to thrive in what is becoming a more complex and contested market. For policymakers and investors, understanding these trends is essential to navigating the next wave of healthcare innovation and economic transformation.